Anthropic Ships Sonnet 5 With Agentic Safety and Pricing Details
1 July 20265 min read
Illustrative image. Cedar S. Insights uses editorial stock photography; images do not depict specific events described in articles.
A European clinical trial reported that sulthiame reduced breathing interruptions in people with moderate to severe obstructive sleep apnea.
ScienceDaily says higher-dose patients experienced up to 47% fewer pauses in breathing and improved oxygen levels during sleep.
The drug is designed to stabilise breathing signals rather than mechanically hold the airway open, which would make it different from CPAP therapy if later studies support use.
Sourcing note: Trial summary and figures are from ScienceDaily. The article treats sulthiame as an investigational or developing option, not an approved replacement for CPAP.
Why It Matters
Sleep apnea care is dominated by devices that many patients struggle to use consistently. A pill-based approach would be clinically significant if larger studies confirm benefit, safety and patient selection.
Primary Sources
Our sourcing: Cedar S. Insights provides source-led editorial analysis. Reported company, institutional and regulatory claims are attributed to their original sources unless stated otherwise.
Corrections: If a material factual error is identified, Cedar S. Insights will update the relevant article and preserve the distinction between the corrected statement and supporting evidence.
Topics
Sleep ApneaSulthiameClinical TrialRespiratory MedicineScienceDaily